WO2015180552A1 - 伏拉塞替及其中间体的制备方法 - Google Patents

伏拉塞替及其中间体的制备方法 Download PDF

Info

Publication number
WO2015180552A1
WO2015180552A1 PCT/CN2015/077897 CN2015077897W WO2015180552A1 WO 2015180552 A1 WO2015180552 A1 WO 2015180552A1 CN 2015077897 W CN2015077897 W CN 2015077897W WO 2015180552 A1 WO2015180552 A1 WO 2015180552A1
Authority
WO
WIPO (PCT)
Prior art keywords
isopropyl
ethyl
methyl
dihydro
preparation
Prior art date
Application number
PCT/CN2015/077897
Other languages
English (en)
French (fr)
Inventor
许学农
Original Assignee
苏州明锐医药科技有限公司
哲人药业南京有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州明锐医药科技有限公司, 哲人药业南京有限公司 filed Critical 苏州明锐医药科技有限公司
Publication of WO2015180552A1 publication Critical patent/WO2015180552A1/zh
Priority to US15/361,248 priority Critical patent/US9688685B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Definitions

  • the invention belongs to the technical field of organic synthesis route design and preparation technology of raw materials and intermediates, and particularly relates to a preparation method of Volasertib and its intermediates.
  • Volasertib is an experimental Polo-like kinase (Plk) inhibitor developed by Boehringer Ingelheim in September 2013 and April 2014, respectively.
  • the FDA and EMEA have awarded technological therapies and orphan drug status for the treatment of patients with acute myeloid leukemia (AML) who are 65 years of age and older and who are not eligible for intensive induction chemotherapy. Since the drug has not been officially listed in China and does not have a standard Chinese translation, the applicant hereby transliterates it as "Vlasset”.
  • Volasertib is designed to inhibit the activity of the regulatory cell mitogen Plk1. This inhibition will prolong cell cycle arrest and lead to apoptosis.
  • Volasertib (I) chemical name N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)- 7-Ethyl-5,6,7,8-tetrahydro-5-methyl-8-isopropyl-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide.
  • the intermediate (B) is prepared by amidation, oxidation, condensation reduction and nitro reduction using 1,4-cyclohexylamine as a raw material:
  • N-cyclohexylmethylpiperazine is used as a raw material to obtain an intermediate (B) by condensation reduction, hydrolysis to salt, amidation and nitro reduction:
  • the object of the present invention is to provide a modification in accordance with the concept of synthesis of green chemistry.
  • the preparation method of the voltazone (I) is simple, the conditions are mild, and the side reaction is small, which is suitable for the industrialization amplification.
  • two intermediates which can be used for the preparation of voltacetate and a preparation method thereof are also provided.
  • the main technical solution provided by the present invention is as follows: a Volasertib (N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl] ring) Hexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-isopropyl-6-oxo-2-pteridinyl]amino a method for preparing 3-methoxybenzamide, I),
  • the preparation method comprises the steps of: an intermediate 2-amino-7-ethyl-7,8-dihydro-5-methyl-8-isopropyl-(7R)-6(5H)-pteridinone ( II) and the intermediate N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-halo-3-methoxybenzamide (III)
  • the nucleophilic substitution reaction produces voltase (I).
  • the present invention also includes the following subsidiary technical solutions:
  • the catalyst for the nucleophilic substitution reaction is cuprous iodide, zinc linide iodide, stannous chloride, palladium chloride or silver iodide, preferably cuprous iodide.
  • the cocatalyst for the nucleophilic substitution reaction is 8-hydroxyquinoline, 2,6-lutidine, 4-dimethylaminopyridine, N-methylmorpholine, N-ethylmorpholine, 1,5- Diazabicyclo[4.3.0]-indol-5-ene, 1,8-diazabicyclo[5.4.0]-undec-7-ene or 1,4-diazabicyclo[2.2. 2] Octane, preferably 8-hydroxyquinoline or 1,8-diazabicyclo[5.4.0]-undec-7-ene.
  • the solvent for the nucleophilic substitution reaction is xylene, dioxane, dimethyl sulfoxide, N,N-dimethylformamide or N,N-dimethylacetamide, preferably dimethyl sulfoxide or N. N-dimethylformamide.
  • the temperature of the nucleophilic substitution reaction is from 100 to 160 ° C, preferably from 110 to 150 ° C.
  • the present invention also provides a voltacetate intermediate having the chemical name of 2-amino-7-ethyl-7,8-dihydro-5-methyl-8-isopropyl-(7R) -6(5H)-pteridin, the chemical formula is as shown in formula II:
  • the preparation method of the voltaceux intermediate (II) comprises the following steps: 2-chloro-7-ethyl-7,8-dihydro-5-methyl-8-isopropyl-(7R)-6 (5H)-pteridinone (IV) is aminated to give 2-(N-allyl)amino-7-ethyl-7,8-dihydro-5-methyl-8-isopropyl-( 7R)-6(5H)-pteridinone (V), compound (V) is obtained by reduction reaction to obtain the voltacetate intermediate 2-amino-7-ethyl-7,8-dihydro-5- Base-8-isopropyl-(7R)-6(5H)-pteridinone (II).
  • the present invention also provides another voltaceux intermediate, the chemical name of which is N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]- 4-halo-3-methoxybenzamide, the chemical formula is as shown in formula III:
  • the preparation method of the voltaceux intermediate (III) comprises the following steps: trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexylamine trihydrochloride (VI) Amidation reaction with 3-methoxy-4-halo-benzoyl chloride (VII) gives the voltexide intermediate N-[trans-4-[4-(cyclopropylmethyl)-1 - piperazinyl]cyclohexyl]-4-halo-3-methoxybenzamide (III).
  • the preparation method of voltaic and the intermediate thereof according to the invention has the advantages of simple process, mild conditions and reduced side reaction, and is suitable for industrial amplification.
  • Embodiment 1 is a diagrammatic representation of Embodiment 1:
  • Triethylamine (75 mg, 0.75 mmol) was added, the temperature was further raised to 140 ° C, and the reaction was carried out for 15 hours, and the reaction was completed by TLC. The temperature was lowered to 50-60 ° C, filtered, and the filter cake was washed with ethyl acetate. The filtrate was washed with brine, EtOAc (EtOAc m.)
  • Embodiment 2 is a diagrammatic representation of Embodiment 1:
  • Ethylenediamine (45 mg, 0.75 mmol) was added, and the temperature was further raised to 120 ° C, and the reaction was carried out for 8 hours, and the reaction was completed by TLC. The temperature was lowered to 50-60 ° C, filtered, and the filter cake was washed with ethyl acetate. The filtrate was washed with brine, EtOAc (EtOAc)EtOAc.
  • Embodiment 3 is a diagrammatic representation of Embodiment 3
  • Embodiment 4 is a diagrammatic representation of Embodiment 4:
  • Embodiment 5 is a diagrammatic representation of Embodiment 5:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明揭示了一种伏拉塞替(Volasertib，I)的制备方法，其制备包括如下步骤：用中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)与中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺(III)发生亲核取代反应，制得伏拉塞替(I)。该制备方法工艺简洁、条件温和且副反应少，适合工业化放大的要求。另外，本发明还揭示了伏拉塞替的中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)和中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺(III)及其制备方法。

Description

伏拉塞替及其中间体的制备方法 技术领域
本发明属于有机合成路线设计及其原料药和中间体制备技术领域，特别涉及一种伏拉塞替(Volasertib)及其中间体的制备方法。
背景技术
伏拉塞替(Volasertib)是由勃林格殷格翰(Boehringer Ingelheim)研发的一种实验性Polo样激酶(polo-like kinase，Plk)抑制剂，该药分别于2013年9月和2014年4月被FDA和EMEA授予突破性的疗法和孤儿药地位，用于65岁及以上、不合适接受强化诱导性化疗方案的急性髓细胞性白血病(AML)患者的治疗。因该药物在我国还未正式上市，还不具有标准的中文译名，故本申请人在此将其音译为“伏拉塞替”。伏拉塞替(Volasertib)被设计用于抑制调节细胞有丝分裂酶Plk1的活性。这一抑制作用将延长细胞周期停滞时间，导致细胞凋亡。
伏拉塞替(Volasertib，I)，化学名为N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-[[(7R)-7-乙基-5，6，7，8-四氢-5-甲基-8-异丙基-6-氧代-2-蝶啶基]氨基]-3-甲氧基苯甲酰胺。
Figure PCTCN2015077897-appb-000001
勃林格殷格翰公司原研的世界专利WO2004/076454、WO2006/018220、WO2007/090844和WO2009/019205等揭示了伏拉塞替及其类似物的制备方法。尽管中间体的制备方法存在差异，但目标产物均是通过中间体2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(A)和N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-氨基-3-甲氧基苯甲酰胺(B)于酸性条件下缩 合制得。
Figure PCTCN2015077897-appb-000002
上述文献还公开了中间体(A)的制备路线为：
Figure PCTCN2015077897-appb-000003
中间体(B)的制备路线有两种，其一，以1，4-环己胺醇为原料，经酰胺化、氧化、缩合还原和硝基还原制得中间体(B)：
Figure PCTCN2015077897-appb-000004
或者，以N-环己基甲基哌嗪为原料，经过缩合还原、水解成盐、酰胺化及硝基还原制得中间体(B)：
Figure PCTCN2015077897-appb-000005
考察上述中间体(A)、(B)和伏拉塞替的合成路线，由于中间体(A)、(B)及伏拉塞替分子结构中多处存在胺基官能团，因而在进行缩合、酰胺化以及还原反应时，环己胺中的伯胺、哌啶环上仲胺以及苯环上的伯胺均会产生竞争性副反应，使纯化难度增加，反应总收率降低。所以，如果能够寻求一种由经典单元反应组成，又可以减少副反应的伏拉塞替及其中间体的合成路线及制备方法，对于伏拉塞替的工业化制备具有较现实的意义。
发明内容
为了克服现有技术中的缺陷，本发明的目的在于按照绿色化学的合成理念，提供一种改 进的伏拉塞替(I)的制备方法，该制备方法的工艺简洁、条件温和且副反应少，适合工业化放大的要求。同时，还提供了两个可用于伏拉塞替制备的中间体及其制备方法。
为了实现上述目的，本发明所提供的主要技术方案如下：一种伏拉塞替(Volasertib，N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-[[(7R)-7-乙基-5，6，7，8-四氢-5-甲基-8-异丙基-6-氧代-2-蝶啶基]氨基]-3-甲氧基苯甲酰胺，I)的制备方法，
Figure PCTCN2015077897-appb-000006
所述制备方法包括如下步骤：中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)和中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺(III)发生亲核取代反应制得伏拉塞替(I)。
Figure PCTCN2015077897-appb-000007
此外，本发明还包括如下附属技术方案：
所述亲核取代反应的催化剂为碘化亚铜、碘化亚锌、氯化亚锡、氯化钯或碘化银，优选碘化亚铜。
所述亲核取代反应的助催化剂为8-羟基喹啉、2，6-二甲基吡啶、4-二甲氨基吡啶、N-甲基吗啉、N-乙基吗啉、1，5-二氮杂二环[4.3.0]-壬-5-烯、1，8-二氮杂双环[5.4.0]-十一-7-烯或1，4-二氮杂二环[2.2.2]辛烷，优选8-羟基喹啉或1，8-二氮杂双环[5.4.0]-十一-7-烯。
所述亲核取代反应的溶剂为二甲苯、二氧六环、二甲亚砜、N，N-二甲基甲酰胺或N，N-二甲基乙酰胺，优选二甲亚砜或N，N-二甲基甲酰胺。
所述亲核取代反应的温度为100-160℃，优选110-150℃。
同时，本发明还提供了一种伏拉塞替中间体，其化学名为2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮，化学式如式II所示：
Figure PCTCN2015077897-appb-000008
所述伏拉塞替中间体(II)的制备方法包括如下步骤：2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(IV)通过胺化反应得到2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(V)，化合物(V)通过还原反应得到所述伏拉塞替中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)。
Figure PCTCN2015077897-appb-000009
同时，本发明还提供了另一种伏拉塞替中间体，其化学名为N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺，化学式如式III所示：
Figure PCTCN2015077897-appb-000010
所述伏拉塞替中间体(III)的制备方法包括如下步骤：反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐(VI)与3-甲氧基-4-卤素-苯甲酰氯(VII)发生酰胺化反应得到所述伏拉塞替中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺(III)。
Figure PCTCN2015077897-appb-000011
所述N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺(III)中的卤素 为氟、氯、溴或碘，优选溴或碘。
相比于现有技术，本发明所涉及的伏拉塞替及其中间体的制备方法，其优点是工艺简洁、条件温和和副反应减少，适合工业化放大的要求。
具体实施方式
以下结合数个较佳实施例对本发明技术方案作进一步非限制性的详细说明。其中原料2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(IV)和反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐(VI)的合成可参见世界专利WO2007090844对相同化合物的制备方法；3-甲氧基-4-卤素-苯甲酰氯(VII)可参考文献《Archiv der Pharmazie》(1985年)，第318卷第1期，p78-84页和文献《Joumal of Natural Products》(2013年)，第76卷第10期，p1916-1922页对相同及类似化合物的合成方法。
实施例一：
氮气保护下，于三口瓶中加入2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)(1.17g，5mmol)、N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-溴-3-甲氧基苯甲酰胺(III)(2.25g，5mmol)、碘化亚铜(142mg，0.75mmol)、8-羟基异喹啉(220mg，0.75mmol)、碳酸钾(760mg，5.5mmol)和50mL N，N-二甲基甲酰胺，升温至100℃，搅拌至溶解。加入三乙胺(75mg，0.75mmol)，继续升温至140℃，反应15小时，TLC检测，反应完成。降温至50-60℃，过滤，滤饼用乙酸乙酯洗涤。滤液用盐水、水洗涤，减压浓缩，乙酸乙酯和正己烷(2∶1)重结晶，得到淡黄色固体伏拉塞替(I)2.42g，收率78.3％。
实施例二：
氮气保护下，于三口瓶中加入2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)(1.17g，5mmol)、N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-碘-3-甲氧基苯甲酰胺 (III)(2.48g，5mmol)、碘化亚铜(142mg，0.75mmol)、8-羟基异喹啉(220mg，0.75mmol)、碳酸钾(760mg，5.5mmol)和50mL N，N-二甲基甲酰胺，升温至100℃，搅拌至溶解。加入乙二胺(45mg，0.75mmol)，继续升温至120℃，反应8小时，TLC检测，反应完成。降温至50-60℃，过滤，滤饼用乙酸乙酯洗涤。滤液用盐水、水洗涤，减压浓缩，乙酸乙酯和正己烷(2∶1)重结晶，得到类白色固体伏拉塞替(I)2.64g，收率85.4％。
实施例三：
于三口瓶中加入2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(IV)(2.68g，10mmol)和烯丙基胺25mL，加热至回流，反应4小时，TLC检测至原料反应完全。冷却，加入纯水50mL，用二氯甲烷萃取3次，合并有机相，无水硫酸钠干燥，减压回收溶剂，所得油状物为2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(V)，无需处理，直接用50mL乙醇溶解，转入一干燥的三口反应瓶，氮气氛下加入三氟化硼乙醚(0.9g，1eq)和5％钯炭(0.3g，10％w/w)，加热至乙醇回流，反应9小时，TLC检测反应完成。减压回收溶剂，剩余物用乙酸乙酯重结晶，得到淡黄色固体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮(II)2.25g，收率90.4％。
实施例四：
于三口反应瓶中加入反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐(VI)(3.47g，10mmol)和四氢呋喃20mL，冰浴下和搅拌下，同时滴加3-甲氧基-4-溴-苯甲酰氯(VII)(2.72g，11mmol)的四氢呋喃20mL溶液和二异丙基乙胺(6.45g，50mmol)的四氢呋喃20mL溶液，滴毕，室温反应5小时，TLC检测反应完成。用50％的氢氧化钠调节pH至9-10，用二氯甲烷萃取三次，合并有机相，用饱和食盐水和水洗涤各一次，无水硫酸钠干燥，减压回收溶剂。残余物用异丙醚重结晶，真空干燥得类白色固体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己 基]-4-溴-3-甲氧基苯甲酰胺(III)3.88g，收率为86.4％。
实施例五：
于三口反应瓶中加入反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐(VI)(3.47g，10mmol)和四氢呋喃20mL，冰浴下和搅拌下，同时滴加3-甲氧基-4-碘-苯甲酰氯(VII)(2.72g，11mmol)的四氢呋喃20mL溶液和二异丙基乙胺(6.45g，50mmol)的四氢呋喃20mL溶液，滴毕，室温反应5小时，TLC检测反应完成。用50％的氢氧化钠调节pH至9-10，用二氯甲烷萃取三次，合并有机相，用饱和食盐水和水洗涤各一次，无水硫酸钠干燥，减压回收溶剂。残余物用甲基叔丁基醚重结晶，真空干燥得类白色固体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-碘-3-甲氧基苯甲酰胺(III)4.08g，收率为82.1％。
需要指出的是，上述实施例仅为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (12)

  1. 一种伏拉塞替的制备方法，
    Figure PCTCN2015077897-appb-100001
    其特征在于所述制备方法包括如下步骤：中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮和中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺在催化剂和助催化剂作用下发生亲核取代反应制得伏拉塞替(I)。
  2. 根据权利要求1所述伏拉塞替的制备方法，其特征在于：中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮的化学式如式II所示：
    Figure PCTCN2015077897-appb-100002
  3. 根据权利要求2所述伏拉塞替的制备方法，其特征在于所述中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮的制备包括如下步骤：2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮通过胺化反应得到2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮，所述2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮通过还原反应得到伏拉塞替中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮。
  4. 根据权利要求1所述伏拉塞替的制备方法，其特征在于中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺的化学式如式III所示：
    Figure PCTCN2015077897-appb-100003
  5. 根据权利要求4所述伏拉塞替的制备方法，其特征在于中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺的制备包括如下步骤：反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐与3-甲氧基-4-卤素-苯甲酰氯发生酰胺化反应得到所述伏拉塞替中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺。
  6. 根据权利要求4所述伏拉塞替的制备方法，其特征在于中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺中的卤素为氟、氯、溴或碘。
  7. 根据权利要求1所述伏拉塞替的制备方法，其特征在于：所述亲核取代反应的催化剂为碘化亚铜、碘化亚锌、氯化亚锡、氯化钯或碘化银；所述亲核取代反应的助催化剂为8-羟基喹啉、2，6-二甲基吡啶、4-二甲氨基吡啶、N-甲基吗啉、N-乙基吗啉、1，5-二氮杂二环[4.3.0]-壬-5-烯、1，8-二氮杂双环[5.4.0]-十一-7-烯或1，4-二氮杂二环[2.2.2]辛烷。
  8. 根据权利要求1所述伏拉塞替的制备方法，其特征在于：所述亲核取代反应的溶剂为二甲苯、二氧六环、二甲亚砜、N，N-二甲基甲酰胺或N，N-二甲基乙酰胺；所述亲核取代反应的温度为100-160℃。
  9. 根据权利要求8所述伏拉塞替中间体的制备方法，其特征在于包括如下步骤：2-氯-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮通过胺化反应得到2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮，所述2-(N-烯丙基)氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮通过还原反应得到所述伏拉塞替中间体2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基-(7R)-6(5H)-蝶啶酮。
  10. 一种伏拉塞替中间体，其化学名为2-氨基-7-乙基-7，8-二氢-5-甲基-8-异丙基 -(7R)-6(5H)-蝶啶酮，化学式如式II所示：
    Figure PCTCN2015077897-appb-100004
  11. 一种伏拉塞替中间体，其化学名为N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺，化学式如式III所示：
    Figure PCTCN2015077897-appb-100005
  12. 一种根据权利要求11所述伏拉塞替中间体的制备方法，其特征在于其包括如下步骤：反式-4-[4-(环丙基甲基)-1-哌嗪基]环己胺三盐酸盐与3-甲氧基-4-卤素-苯甲酰氯发生酰胺化反应得到所述伏拉塞替中间体N-[反式-4-[4-(环丙基甲基)-1-哌嗪基]环己基]-4-卤素-3-甲氧基苯甲酰胺。
PCT/CN2015/077897 2014-05-26 2015-04-30 伏拉塞替及其中间体的制备方法 WO2015180552A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/361,248 US9688685B2 (en) 2014-05-26 2016-11-25 Method for preparing volasertib and intermediate thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410225833.8A CN104003989B (zh) 2014-05-26 2014-05-26 伏拉塞替及其中间体的制备方法
CN201410225833.8 2014-05-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/361,248 Continuation US9688685B2 (en) 2014-05-26 2016-11-25 Method for preparing volasertib and intermediate thereof

Publications (1)

Publication Number Publication Date
WO2015180552A1 true WO2015180552A1 (zh) 2015-12-03

Family

ID=51364922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/077897 WO2015180552A1 (zh) 2014-05-26 2015-04-30 伏拉塞替及其中间体的制备方法

Country Status (3)

Country Link
US (1) US9688685B2 (zh)
CN (1) CN104003989B (zh)
WO (1) WO2015180552A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104003989B (zh) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法
WO2016206619A1 (zh) * 2015-06-26 2016-12-29 苏州晶云药物科技有限公司 Volasertib及其三盐酸盐的新晶型

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018220A2 (de) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von dihydropteridinonen
CN1745081A (zh) * 2003-02-26 2006-03-08 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
CN101379064A (zh) * 2006-02-08 2009-03-04 贝林格尔·英格海姆国际有限公司 二氢蝶啶酮衍生物的三氢氯酸盐形式及其制备方法
CN103168040A (zh) * 2010-10-12 2013-06-19 贝林格尔.英格海姆国际有限公司 制备二氢喋啶酮的方法及其中间体
CN104003989A (zh) * 2014-05-26 2014-08-27 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745081A (zh) * 2003-02-26 2006-03-08 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
WO2006018220A2 (de) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von dihydropteridinonen
CN101379064A (zh) * 2006-02-08 2009-03-04 贝林格尔·英格海姆国际有限公司 二氢蝶啶酮衍生物的三氢氯酸盐形式及其制备方法
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
CN103168040A (zh) * 2010-10-12 2013-06-19 贝林格尔.英格海姆国际有限公司 制备二氢喋啶酮的方法及其中间体
CN104003989A (zh) * 2014-05-26 2014-08-27 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法

Also Published As

Publication number Publication date
US20170073350A1 (en) 2017-03-16
US9688685B2 (en) 2017-06-27
CN104003989A (zh) 2014-08-27
CN104003989B (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
JP6598974B2 (ja) Ｂ型肝炎ウイルス感染症の治療および予防のための新規な三環式４−ピリドン−３−カルボン酸誘導体
JP6435054B2 (ja) Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体
CN114008033A (zh) 胰高血糖素样肽1受体激动剂
US20190152976A1 (en) Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016082605A1 (zh) 帕博西尼的制备方法
WO2016082604A1 (zh) 帕博西尼的制备方法
JP6787998B2 (ja) 置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法
CA2990088A1 (en) Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2015123437A1 (en) Cyclopropylamines as lsd1 inhibitors
JP2012521411A (ja) アログリプチンの調製プロセス
CA2888480C (en) Heteroaryl linked quinolinyl modulators of ror.gamma.t
US20150152083A1 (en) Compounds and Compositions for Modulating EGFR Activity
JP2019524699A (ja) イミダゾピリジンアミンフェニル誘導体およびその使用
CA3070069C (en) Improved process for preparing aminopyrimidine derivatives
JP2020189852A (ja) キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用
WO2017016410A1 (zh) 抗肿瘤药物ap26113的制备方法
AU2022217353A1 (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
WO2014154723A1 (en) Novel pyrrole derivatives for the treatment of cancer
WO2015103927A1 (zh) 尼洛替尼中间体的制备方法
JP2023162363A (ja) 広域スペクトルの抗ウイルス組成物及び方法
CN105198821A (zh) 洛昔替尼的制备方法
WO2015180552A1 (zh) 伏拉塞替及其中间体的制备方法
IL300352A (en) The compositions for cutting and fusion modulation
KR101941794B1 (ko) 아미노설포닐계 화합물, 이의 제조 방법 및 용도
CN101456862B (zh) 含有吡唑并嘧啶酮的苯基胍衍生物、其药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 01.02.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15800577

Country of ref document: EP

Kind code of ref document: A1